|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Department of Genetics and Pathology, Rudbeck
Laboratory, Uppsala University, Uppsala, Sweden, and the Department of
Plant Biology, Uppsala Genetic Center, Swedish University of
Agricultural Sciences, Uppsala, Sweden.
All-trans retinoic acid (ATRA) is a potential
therapeutic agent for the treatment of hematopoietic malignancies,
because of its function as an inducer of terminal
differentiation of leukemic blasts. Although the efficacy of ATRA
as an anticancer drug has been demonstrated by the successful treatment
of acute promyelocytic leukemia (APL), the molecular mechanisms of
ATRA-induced cell cycle arrest of myeloid cells have not been
fully investigated. In this study, we show that the onset of
ATRA-induced G0/G1 arrest of human monoblastic
U-937 cells is linked to a sharp down-regulation of c-Myc and cyclin E
levels and an increase in p21WAF1/CIP1 expression. This is
followed by an increase in p27Kip1 protein expression
due to enhanced protein stability. The importance of an early decrease
in Myc expression for these events was demonstrated by the failure of a
U-937 subline with constitutive exogenous expression of v-Myc to cell
cycle arrest and regulate cyclin E and p27Kip1 in response
to ATRA. Preceding the initiation of G1 arrest, a transient
rise in retinoblastoma protein (pRb), p107, and cyclin A levels was
detected. Later, a rapid fall in the levels of cyclins A and B and a
coordinate dephosphorylation of pRb at Ser780, Ser795, and Ser807/811
coincided with the accumulation of cells in G1. These
results thus identify a decrease in c-Myc and cyclin E levels and a
posttranscriptional up-regulation of p27Kip1 as important
early changes, and position them in the complex chain of events
regulating ATRA-induced cell cycle arrest of myeloid cells.
(Blood. 2002;99:2199-2206) Hematopoietic tumors often arise as a consequence
of uncontrolled proliferation of immature blasts, failing to terminally differentiate into mature blood cells.1 A hallmark of
terminal differentiation is an irreversible arrest in the
G0/G1 phase of the cell cycle. This arrest
involves the coordinate regulation of signals that negatively control
the cell cycle machinery and inhibit the G1/S transition.
At the heart of the cell cycle lies the regulation of cyclin-dependent
kinases (CDKs), which control the phosphorylation of several
substrates, including retinoblastoma protein (pRb) family
members, and thus the transcriptional activation or repression
of E2F target genes important for cell cycle
progression.2-4 The G1/S transition is
believed to be sequentially controlled by D-type cyclins, which
activate CDK4 and CDK6, and subsequently by cyclin E, which associates
with CDK2.5 CDK activity is dependent on association with
cyclins and subsequent phosphorylation-dephosphorylation events, and
may be inhibited by 2 different groups of CDK inhibitors (CKIs), namely
the Ink4 family and the Cip/Kip family.6 Thus, growth
arrest associated with differentiation could be achieved by several
mechanisms including the down-regulation of cyclins or
up-regulation of CKIs or both. The critical events leading to a
cell cycle arrest are, however, likely to be specific for each mode of
induction of differentiation and may differ for each particular
cell type.
Proliferation and differentiation of hematopoietic cells can be
regulated by a number of physiologic agents, including
all-trans retinoic acid (ATRA). ATRA treatment triggers
terminal differentiation and growth arrest of several established human
myeloid cell lines in vitro and has also proven to be effective in the
clinical treatment of acute promyelocytic leukemia (APL) by inducing
differentiation and apoptosis of the immature blasts.7,8
Although the biologic effects of ATRA are well characterized, the
molecular mechanisms regulating these processes are largely unknown.
The cell cycle arrest associated with ATRA-induced differentiation may
involve regulation of the expression of both cyclins and CKIs, affect phosphorylation status of CDKs, and ultimately trigger
dephosphorylation of pRb pocket proteins. However, although previous
studies on ATRA-induced growth arrest of myeloid cells have implicated
individual proteins, for example,
p21WAF1/CIP1,9-11 a more complete
investigation of the regulation of the cell cycle machinery is required
to understand the relative importance of different events during the
differentiation process.
To gain further insight into the ATRA-induced events leading to
G0/G1 arrest during terminal differentiation of
human myeloid cells, we have performed a comprehensive analysis of the
regulation of CKIs, cyclins, CDKs, and pRb pocket proteins during
terminal differentiation. The well-characterized human U-937 cell
line12 was chosen as a model system. This established model
of monocytic differentiation can be induced to undergo terminal
differentiation by 12-O-tetradecanoyl phorbol-13-acetate (TPA),
vitamin D3, and ATRA, resulting in
G0/G1-arrested cells with distinct
phenotypes.13-15 By kinetically correlating messenger RNA
(mRNA) and protein expression levels of important cell cycle regulatory
genes with the cell cycle distribution in U-937 cells after ATRA
induction, we determined the relative order of these events. This
enabled us to identify a temporal pattern of changes in gene
expression: (1) a rapid up-regulation of p21 and down-regulation of
c-Myc; (2) a down-regulation of cyclin E and up-regulation of
p27, at the onset of the cell cycle arrest; (3) an early, transient
increase in cyclins, pRb, and p107 expression; and finally (4)
down-regulation of cyclins A and B and dephosphorylation of pRb,
coincidental to the accumulation of cells in the G1 phase
of the cell cycle. Taken together our results demonstrate that a series
of complex regulatory events lead to an irreversible cell cycle arrest
associated with ATRA-induced myeloid differentiation, in which a rapid
reduction of c-Myc and cyclin E levels in conjunction with a
posttranscriptional increase in p27 expression appears to be pivotal.
Cell culture and ATRA induction
Cell cycle and immunofluorescence analysis
The surface antigen expression was analyzed by immunofluorescence using flow cytometry (FACScan; Becton Dickinson). Briefly, the cells were washed twice with PBS, incubated with phycoerythrin (PE)-conjugated antibodies on ice for 30 minutes and finally washed twice with PBS plus 0.5% fetal calf serum (FCS). The PE-conjugated antibodies used were Leu M5 (CD11c) (Becton Dickinson) and IgG2b (Dako, Glostrup, Denmark). Statistical analysis Statistical analysis was done by analysis of variance (ANOVA) followed by multiple comparison by the Fisher method using the StatView computer program. An asterisk denotes P < .05 (Figures 4 and 6).RNA isolation and RNAse protection assay Total RNA was isolated using the RNAgents Total RNA Isolation System (Promega, Madison, WI) according to the manufacturer's instructions. RNA concentration was determined by measuring the absorbance at 260 nm using a spectrophotometer.The RNAse protection assay (RPA) was done with 7 µg of total RNA using the RiboQuant Multi-Probe RNase Protection Assay system (Pharmingen, Becton Dickinson, Stockholm, Sweden) according to the manual and 32P-UTP (Sigma) labeled multitemplate probes (Pharmingen). Multitemplate probes hCC-2 (p130, pRb, p107, p53, p57, p27, p21, p19, p18, p16, p14/15, L32, GAPDH) and hCYC-1 (cyclin A, cyclin B, cyclin C, cyclin D1, cyclin D2, cyclin D3, cyclin A1, L32, GAPDH) were used to analyze expression of CKI and cyclin mRNA. Cell lysates and Western blot analysis Cells were collected by centrifugation at 1500 rpm, washed once with PBS, lysed in 1% NP-40, 0.1 M Tris-HCl, pH 8.0, 0.15 M NaCl, and 5 mM EDTA with complete protease inhibitor (Boehringer Mannheim, Mannheim, Germany), 1 mM Dithiotreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 mM NaVO3, 10 mM NaF, 50 µM NaMoO4, and 1 mM ZnCl2, and incubated on ice for 15 minutes. Cell lysates were spun 15 minutes at 14 000 rpm at 4°C in a chilled microcentrifuge, supernatants were collected, and the protein content was determined using the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA) according to the manufacturer's recommendations. Equal amounts (10-15 µg) of extracts were fractionated on Novex NuPAGE (4%-12%, 10%) precast gels using the Novex electrophoresis and blotting system (Novex, San Diego, CA). The membrane (Hybond-C extra, Amersham, Uppsala, Sweden) was blocked in 5% dry milk in .1% Tween-Tris buffered Saline (TTBS) for 1 hour at room temperature. Incubation with primary antibody was done at 4°C overnight, and then the membranes were washed 5 times in TTBS, and incubated with secondary horseradish peroxidase (HRP)-linked antibodies (Dako) for 1 hour at room temperature. After washing the membranes extensively in TTBS, antibody binding was detected using enhanced chemoluminescence plus (Amersham Pharmacia Biotech, Uppsala, Sweden). Primary antibodies used were -cyclin A (C-19), -cyclin B (H-20), -p27 (C-19), -cyclin D2
(C-17), -cyclin D3 (C-16), -cyclin E (HE12), -p107 (C-18),
-p130 (211.6), and -actin (I-19) (Santa Cruz
Biotechnology, Santa Cruz, CA) and the Phosphoplus Rb (Ser780, Ser795,
Ser807/811) antibody kit (Cell Signaling Technology, Beverly, MA).
Western blots were performed with extracts from at least 3 independent ATRA-induced kinetic experiments and routinely stained by Ponceau S to
control for protein loading differences.
Assay for p27Kip1 protein stability Exponentially growing U-937 cells and cells induced to differentiate in medium containing 1 µM ATRA for 72 hours were analyzed. To inhibit new protein synthesis the cells were treated with 100 µg/mL cycloheximide (Sigma) at time zero and p27 degradation followed for 8 hours. Whole cell lysates were prepared at indicated times and subjected to Western blot analysis as described above using primary antibodies directed against p27 or actin. The bands were quantified and the p27 protein half-life was estimated from the slope of the curve.Immunoprecipitation Cell lysates were prepared as described above and equal amounts of protein were incubated with rabbit pan-Myc antibodies IG921 and protein A-agarose beads at 4°C overnight. The immunocomplexes were washed 3 times in lysis buffer, and boiled at 95°C for 5 minutes prior to electrophoresis on a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. The fractionated protein was transferred from the gel to a nitrocellulose membrane and subjected to immunoblotting as described, using biotin-coupled C-33 monoclonal pan-Myc antibodies (Santa Cruz Biotechnology) followed by streptavidin-HRP conjugates. The C-33 antibodies were conjugated with 10 µg biotin-X-NHS (Calbiochem-Novabiochem, La Jolla, CA) per milligram antibody in 0.1 M NaHCO3, pH 7.4, 0.1 M NaCl for 1 hour at room temperature followed by dialysis in PBS.In vitro kinase assay Whole cell lysates were prepared as described above, with the exception of the use of 150 mM NaCl, 0.5% NP-40, and 50 mM Tris pH 6.8 lysis buffer. Equal amounts of protein were subjected to immunoprecipitation with 2 µg CDK2, CDK4, or CDK6 antibodies for 2 to 3 hours at 4°C, and then protein G-Sepharose beads were added before a second incubation 1 to 2 hours at 4°C. The immunoprecipitates were washed 3 times in lysis buffer and 3 times in kinase buffer (20 mM Tris pH 7.5, 4 mM MgCl2). The beads were suspended in 10 µL reaction buffer containing 4 mM Tris, pH 7.5, 0.8 mM MgCl2, 1 µg recombinant pRb (769, Santa Cruz) and 32P- -adenosine triphosphate, and incubated for 30 minutes at 37°C. Prior to loading on 4% to 12% NuPAGE gels (Novex),
the samples were suspended in sample buffer with reducing agent
(Novex), boiled at 95°C for 5 minutes, and briefly centrifuged. The
amount of labeled pRb was quantified using a Fuiji Bas 2000 Imaging
System (Fuiji, Tokyo, Japan).
ATRA-induced G0/G1 arrest in U-937 cells is associated with reduced levels of cyclins A, B, D3, and E The kinetics of ATRA-induced cell cycle arrest were determined by flow cytometric analysis of PI-labeled nuclei. U-937 cells were induced by ATRA and harvested at the indicated times; cell cycle distribution was analyzed as described in "Materials and methods" (Figure 1A). Cells started to accumulate in the G0/G1 phase of the cell cycle between 24 and 48 hours of ATRA treatment, and the percentage of cells in the G0/G1 phase continued to increase to over 90% after 96 hours of induction. To further analyze the kinetics of ATRA-induced differentiation, the expression of the surface antigen p150.95/CD11c, indicative of monocyte/macrophage differentiation,22 was determined by FACS analysis after 24, 48, 72, and 96 hours of ATRA treatment (Figure 1B). The expression of CD11c inversely correlated with the percentage of cycling cells (S+G2/M phase cells), coupling differentiation to accumulation of cells in the G0/G1 phase of the cell cycle.
Cell cycle progression is controlled by cyclins and CKIs, which
determine the activity of cyclin-dependent kinases. To determine the
expression of cyclins during U-937 G0/G1 arrest
after ATRA induction, RPA was performed using RNA from untreated or
treated cells and a multitemplate cyclin probe (h-CYC-1). A marked
reduction in cyclin A and cyclin B mRNA was observed after 72 hours of
ATRA treatment (Figure 2A). Both cyclin A
and cyclin B levels are associated with the G2 phase of the
cell cycle and are down-regulated in G1.2 The
levels of cyclins C, A1, D1, and D2 mRNA were not appreciably affected
by ATRA treatment when comparing several experiments, whereas cyclin D3
mRNA levels were slightly down-regulated during differentiation.
Western blot analysis confirmed a sharp decrease in both cyclin A and B protein levels occurring after 72 hours of ATRA induction (Figure 2B). The levels of cyclins are controlled both by transcriptional and posttranscriptional mechanisms; therefore, the protein levels of G0/G1 cyclins D1, D2, and D3 were also analyzed. Whereas cyclin D1 was not detectable in these cells, the level of cyclin D2 was unchanged, and the cyclin D3 protein level was decreased slightly during differentiation. Cyclin E is known to play a role in the G0/G1 transition, but there was no probe for this cyclin in the RPA template set used. Instead, the cyclin E protein level was determined by Western blot analysis. Interestingly, coinciding with the onset of cell cycle arrest, cyclin E was found to be down-regulated after 24 to 48 hours of ATRA stimulation (Figure 2B). CKIs p21WAF1/CIP1 and p27Kip1 are up-regulated by ATRA treatment of U-937 cells, correlating to the onset of G0/G1 arrest The levels of CKIs were monitored using a multitemplate CKI probe (hCC-2; Figure 3A). An increase in p21 mRNA was detected after 24 hours of ATRA induction, as previously reported by Liu et al.9 In addition, we could detect a slight down-regulation of p16, a CDK inhibitor associated with D-type cyclins. The levels of p130, pRb, p53, p57, p27, p19, p18, and p14/15 mRNA remained unchanged.
The RPA analysis showed that p27 mRNA levels remained unchanged after ATRA induction. However, p27 up-regulation can occur by posttranscriptional mechanisms, and has previously been reported to be induced by vitamin D3 treatment of U-937 cells.23 Therefore, the p27 protein level was monitored during ATRA-induced differentiation of U-937 cells. Western blot analysis showed an increase in p27 protein starting after 48 hours of induction (Figure 3B), coinciding with cell cycle arrest. To determine if ATRA treatment affected p27 protein stability, the half-life of p27 was analyzed at 72 hours of induction by following protein levels after 1, 2, 4, 6, and 8 hours after blocking protein synthesis by cycloheximide treatment. The estimated half-life of p27 was approximately 3 to 4 hours in exponentially growing U-937 cells, whereas there was a clear stabilization of p27 protein in cells differentiated by ATRA for 72 hours, consistent with reported observations in ATRA-differentiated neuroblastoma cells.24 Changes in the levels of cyclins and CKIs are reflected by down-regulation of CDK 2-, 4-, and 6-associated activity and dephosphorylation of pRb Cyclins and CKIs regulate the activity of CDKs, which in turn regulate phosphorylation of several substrates, including pRb. Phosphorylation of specific pRb serine or threonine residues has been shown to regulate binding to different targets, including E2F and the c-Abl tyrosine kinase.25,26 Because we observed down-regulation of cyclins A, B, D3, and E and up-regulation of p21 and p27, which may potentially alter the activities of CDKs 2, 4, and 6, the activities of these CDKs were determined through an in vitro kinase assay using pRb as a substrate. A significant (P < .05) reduction in both CDK4, CDK6, and, most markedly, CDK2 activity was detected after 72 hours of ATRA stimulation (Figure 4A). Next, to directly determine the kinetics of changes in pRb phosphorylation associated with ATRA-induced differentiation, cells were induced by ATRA, whole cell lysates were prepared at the indicated times, and Western blot analysis was performed using antibodies directed against pRb phosphorylated on Ser780 or Ser795, important for binding to E2F,25 or Ser-807/811, regulating binding to c-Abl,26 or total levels of pRb (Figure 4B). As expected, differentiation as the result of ATRA treatment was linked to the disappearance of hyperphosphorylated pRb, specifically involving dephosphorylation of Ser780, Ser795 and Ser807/811 with very similar kinetics.
The other members of the retinoblastoma family of pocket proteins, p107 and p130, have also been shown to be important in cell cycle regulation and differentiation.27,28 Similar to the situation for pRb, the function of p130 in cell cycle regulation is determined by both the actual protein level and the phosphorylation status. To determine if there was a change in the level of p130 or its phosphorylation status during differentiation, whole cell lysates of ATRA-induced cells were subjected to electrophoresis on a low-density gel followed by Western blot analysis using p130 antibodies (Figure 4C). There was a slight increase in p130 levels transiently after 24 hours of ATRA treatment, and a drop in both phosphorylated and total p130 after 120 hours of induction. Interestingly, p107 protein levels were regulated in a similar fashion, increasing transiently after 24 hours of ATRA induction, a point before any apparent accumulation in the G1 phase of the cell cycle can be observed, and the p107 expression thereafter continues to decline throughout the 96-hour period of ATRA induction studied (Figure 4D). However, only p107 appeared to be regulated on the mRNA level (Figure 2B). ATRA induces down-regulation of cyclin E and up-regulation of p27KIP1 in the ATRA-responsive human myeloid leukemic cell lines HL-60 and NB-4 Next, we wanted to determine whether the regulation of p27 and cyclin E, similar to the more well-established changes in Myc29,30 and p21,9-11 is a common event linked to cell cycle arrest during myeloid differentiation induced by ATRA. Therefore, we studied the regulation of these proteins in the ATRA-sensitive human myeloid cell lines HL-60 and NB-4. HL-60 cells arrest in the G0/G1 phase of the cell cycle in response to ATRA treatment, whereas NB-4 cells arrest in a non-G1-restricted manner, at all points in the cell cycle31,32 (and data not shown). After 96 hours of ATRA stimulation, the level of p27 protein was increased in both NB-4 and HL-60 cells, whereas the cyclin E level was decreased (Figure 5).
Down-regulation of c-Myc precedes the G0/G1 arrest and is necessary for regulation of cyclin E and p27Kip1 Previous reports have identified c-Myc as a regulator of cyclin E-CDK2 activity through induction of cyclin E expression and inhibition of the association of p27 with cyclin E-CDK2 complexes.33,34 Also, cyclin E-CDK2 complexes have been shown to regulate p27 protein levels through phosphorylation on Thr187.35 This phosphorylation is a prerequisite for the proteosome-dependent degradation of p27.36 Therefore, the observed ATRA-induced decrease in cyclin E levels and subsequent increase in p27 protein may be due to a down-regulation of c-Myc. To determine the protein levels of c-Myc during differentiation, lysates from ATRA-treated cells were immunoprecipitated using pan-Myc antibodies, and analyzed by Western blot. A decrease in the c-Myc protein levels was initiated after 12 hours of ATRA treatment and continued throughout differentiation (Figure 6A), preceding U-937 cell cycle arrest and changes in the levels of cyclin E and p27. This raised the question of whether there is a causal relationship between the reduction of Myc and the down-regulation of cyclin E, and the following up-regulation of p27. To address this possibility we used a U-937 subline constitutively expressing v-Myc, U-937-myc-2.19,37 The U-937-myc-2 and the parental control cells, U-937-GTB, were induced by ATRA and the cell cycle distribution was analyzed during 96 hours. Only a small reduction in the percentage of cycling cells was observed for the U-937-myc-2 cells, whereas U-937-GTB cells became G1 arrested (Figure 6B). Figure 6C shows that U-937-myc-2 cells fail to down-regulate the expression of cyclin E and up-regulate p27 at 72 hours after induction, suggesting that the down-regulation of c-Myc is a prerequisite for these changes.
The successful treatment of APL patients with ATRA demonstrates that external signals can overcome the block of differentiation in myeloid leukemic cells in vivo.7 Although leukemias and lymphomas represent a diverse group of tumors that can arise as a consequence of several different genetic changes, extensive work done in established leukemic cell lines suggests that ATRA or synthetic retinoid derivatives may be effective as therapeutic agents in the treatment also of other types of myeloid malignancies than APL. Identifying the critical subset of cell cycle control genes involved in ATRA-induced growth arrest of myeloid cells is important for the understanding of the molecular events underlying the therapeutic potential of ATRA treatment. Much research interest has been focused on the CKIs with respect to the molecular events initiating a G1 cell cycle arrest. During normal myeloid differentiation from CD34+ hematopoietic progenitors a progressive increase in p21 mRNA and protein is observed.38 Similarly, an early ATRA-induced up-regulation of p21 has been described in leukemic cell lines, for example, U-937, HL-60, and NB-4 cells.9-11,39 The promoter of p21 has been shown to contain a retinoic acid response element (RARE), directly linking activation of the RAR/RXR nuclear receptor complex to induction of p21 expression.9 However, the ATRA-induced level of p21 protein in U-937 cells is relatively low as compared to TPA-induced U-937 cells, and only detectable after immunoprecipitation in our system (data not shown). Therefore, we expected that other CKIs would also be up-regulated by ATRA and that they would contribute to the G0/G1 arrest. The level of p27 mRNA was found to be constant during differentiation. However, the half-life for the p27 protein increased in ATRA-differentiated U-937 cells. This indicates that the mechanism for p27 up-regulation is, at least partially, due to a stabilization of the p27 protein, consistent with findings in ATRA-induced neuroblastoma.24 During hematopoiesis a low expression of p27 protein is detected in early progenitors and continues throughout myeloid differentiation with increased levels or subcellular redistribution (or both) at later stages.40,41 Moderate levels of p27 protein are found in undifferentiated U-937 cells, and it is likely that the observed reduction in cyclin E levels contributes to the following increase in p27 stability after ATRA treatment, because cyclin E-CDK2 complexes can target p27 for degradation through phosphorylation on Thr187.35,36 The general relevance of cyclin E and p27 regulation for differentiation-associated growth arrest of myeloid cells was confirmed in ATRA-induced NB-4 and HL-60 cells. Down-regulation of c-Myc is an important early event that has been connected to terminal differentiation and growth arrest of several cell types,29,30 including U-937.19,37 We observe a decrease in c-Myc levels within 12 hours of ATRA stimulation and a continued down-regulation throughout differentiation. Myc plays a dual role in regulating the activity of cyclin E-CDK2 complexes, primarily via the inhibition of p27, either by induction of cyclin D1 and cyclin D2 resulting in p27 sequestration33,34,42,43 or by direct repression of the p27 promoter,44 but also through direct or indirect transcriptional activation of the cyclin E gene.34 Consequently, changes resulting from the early down-regulation of c-Myc may directly affect the cell cycle machinery and be important for the initiation of G0/G1 arrest. Two observations place c-Myc upstream of the other changes in cell cycle control proteins. First, the kinetics of c-Myc down-regulation is rapid and precedes subsequent changes in cyclin E and p27. Second, we provide evidence that constitutive expression of a v-myc gene prevents reduction of cyclin E and increase in p27 and the consecutive G1 arrest. An early reduction in CDK activity, initiating the
G0/G1 arrest in response to ATRA treatment of
U-937 cells, appears to be largely dependent on the marked
down-regulation of cyclin E in combination with up-regulation of p21
and p27. This is later followed by a fall in cyclin A and B expression,
coincident with the accumulation of cells in G1 (Figure
7A). The observed pattern of cyclin E, cyclin A, and cyclin B expression in ATRA-induced U-937 cells is
reminiscent of that in cells undergoing myeloid differentiation from
normal hematopoietic progenitors, with a high expression during the
proliferative phase followed by down-regulation at the terminal
stage.45 In contrast, the sustained expression of cyclin
D2 and the marginal reduction of cyclin D3 levels during ATRA-induced
cell cycle arrest is clearly different as compared to normal myeloid
differentiation or, for example, to the G1 arrest that is
induced in response to the withdrawal of mitogenic signals (mainly
affecting D-type cyclins).5 This difference may either be
the consequence of the leukemic nature of the U-937 cells or a
particular feature of ATRA-induced differentiation.
Changes in the expression of cyclins and CKIs in response to ATRA treatment were followed by down-regulation of CDK2, CDK4, and CDK6 activity and dephosphorylation of pRb at specific serine residues. The most apparent dephosphorylation of pRb occurs after 72 hours of induction, although an elevation in hypophosphorylated pRb is evident already after 24 hours of ATRA induction, when taking the increase in total pRb into account (Figure 4 and Figure 7B). During the cell cycle progression, pRb is sequentially phosphorylated by different cyclin-CDK complexes.46 Down-regulation of cyclin E precedes dephosphorylation of pRb at Ser780, Ser795, and Ser807/811, and could therefore potentially affect other phosphoacceptor sites. Phosphorylation of pRb by cyclin E-CDK2 has been suggested to prevent E2F binding; therefore, a reduction in cyclin E-CDK2 activity would be predicted to inhibit E2F function and expression of S-phase genes.3,47 Thus, the presence of hypophosphorylated pRb could potentially be important to preclude re-entry into S phase and thereby establish an irreversible cell cycle exit in the terminally differentiated cell. The intimate link between terminal differentiation and cell cycle arrest makes it difficult to assign a particular function of an individual protein to either of the 2 processes. Also, several of the cell cycle regulatory proteins may have dual functions. For instance, the function of pRb family proteins has also been linked to differentiation in various cell systems.27 Interestingly, expression of an antisense pRb construct in U-937 cells, which decreased pRb levels, resulted in defects in ATRA-induced differentiation, but not cell cycle arrest.48 Up-regulation of p21 and p27 may also impinge on the differentiation process; for example, up-regulation of p21 in APL cells has been reported to be important for commitment to differentiation, but not required for cell cycle arrest.39 Forced expression of p21 or p27 has been suggested to induce markers of differentiation in U-937 cells,49 supporting this notion. Typically, it appears that during induced differentiation myeloid cells traverse one or several cell cycles, before the associated G1 arrest is established.39,49,50 Moreover, the proliferative burst after vitamin D3 treatment of U-937 cells is accompanied by a transient up-regulation of cyclins, p27, and p21.49 In agreement with this observation, we observed a transient up-regulation of cyclins A and D2, as well as pRb and p107 within the first 24 hours of ATRA treatment. A transient up-regulation of p107 has recently been suggested to be important for adipocyte differentiation.51 It remains to be shown if similar links between the transient up-regulation of cell cycle control proteins and terminal differentiation exist in ATRA-induced U-937 cells. The main new finding in this paper is that the initiation of ATRA-induced cell cycle arrest in U-937 cells is preceded by down-regulation of c-Myc, necessary for a coordinate fall in cyclin E levels and up-regulation of p27. Although a schematic blueprint of differentiation-associated regulation of cell cycle control proteins in myeloid cells has been drawn by this study, the molecular mechanism of ATRA-induced regulation of cyclins, CDKs, and CKIs warrants further investigation
We thank Lina Dimberg for critical reading of the manuscript.
Submitted June 14, 2001; accepted November 14, 2001.
Supported by the Swedish Cancer Society, the Magnus Bergwall Foundation, the HKH Lovisa/Tielman Foundation, the Hans von Kantzow Foundation, the King Gustaf V's 80 Year Foundation, and the Åke Wiberg Foundation.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Fredrik Öberg, Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, S-751, 85 Uppsala, Sweden; e-mail: fredrik.oberg{at}genpat.uu.se.
1. Sawyers CL, Denny CT, Witte ON. Leukemia and the disruption of normal hematopoiesis. Cell. 1991;64:337-350[CrossRef][Medline] [Order article via Infotrieve]. 2. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995;11:211-219[Medline] [Order article via Infotrieve].
3.
Dyson N.
The regulation of E2F by pRB-family proteins.
Genes Dev.
1998;12:2245-2262 4. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature. 1998;391:597-601[CrossRef][Medline] [Order article via Infotrieve].
5.
Sherr CJ, Roberts JM.
CDK inhibitors: positive and negative regulators of G1-phase progression.
Genes Dev.
1999;13:1501-1512 6. Vidal A, Koff A. Cell-cycle inhibitors: three families united by a common cause. Gene. 2000;247:1-15[CrossRef][Medline] [Order article via Infotrieve].
7.
Warrell RP Jr, de The H, Wang ZY, Degos L.
Acute promyelocytic leukemia [see comments].
N Engl J Med.
1993;329:177-189 8. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med. 2001;7:680-686[CrossRef][Medline] [Order article via Infotrieve].
9.
Liu M, Iavarone A, Freedman LP.
Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation.
J Biol Chem.
1996;271:31723-31728 10. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene. 1994;9:3397-3406[Medline] [Order article via Infotrieve]. 11. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, el-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene. 1994;9:3389-3396[Medline] [Order article via Infotrieve]. 12. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer. 1976;17:565-577[Medline] [Order article via Infotrieve]. 13. Nilsson KA, LC Gahmberg CG, Forsbeck K. Differentiation in vitro of human leukemia and lymphoma cell lines. In: Serrou B, ed. International Symposium on New Trends in Human Immunology and Cancer Immuno-therapy. Paris, France: Doin Editeurs; 1980.
14.
Olsson IL, Breitman TR.
Induction of differentiation of the human histiocytic lymphoma cell line U-937 by retinoic acid and cyclic adenosine 3':5'-monophosphate-inducing agents.
Cancer Res.
1982;42:3924-3927
15.
Olsson I, Gullberg U, Ivhed I, Nilsson K.
Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol.
Cancer Res.
1983;43:5862-5867 16. Larsson L-G, Ivhed I, Öberg F, Pettersson M, Nilsson K. c-jun is induced to high continuous expression during differentiation of hematopoietic cells and is regulated independently from c-fos. Leuk Lymphoma. 1991;4:193-204. 17. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature. 1977;270:347-349[CrossRef][Medline] [Order article via Infotrieve].
18.
Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R.
NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3).
Blood.
1991;77:1080-1086
19.
Larsson LG, Ivhed I, Gidlund M, Pettersson U, Vennstrom B, Nilsson K.
Phorbol ester-induced terminal differentiation is inhibited in human U-937 monoblastic cells expressing a v-myc oncogene.
Proc Natl Acad Sci U S A.
1988;85:2638-2642 20. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983;3:323-327[CrossRef][Medline] [Order article via Infotrieve].
21.
Bahram F, Wu S, Oberg F, Luscher B, Larsson LG.
Posttranslational regulation of Myc function in response to phorbol ester/interferon-gamma-induced differentiation of v-Myc-transformed U-937 monoblasts.
Blood.
1999;93:3900-3912 22. Miller LJ, Schwarting R, Springer TA. Regulated expression of the Mac-1, LFA-1, p150.95 glycoprotein family during leukocyte differentiation. J Immunol. 1986;137:2891-2900[Abstract].
23.
Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP.
Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937.
Genes Dev.
1996;10:142-153 24. Borriello A, Pietra VD, Criscuolo M, et al. p27Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation. Oncogene. 2000;19:51-60[CrossRef][Medline] [Order article via Infotrieve]. 25. Knudsen ES, Wang JY. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol. 1997;17:5771-5783[Abstract].
26.
Knudsen ES, Wang JY.
Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites.
J Biol Chem.
1996;271:8313-8320 27. Lipinski MM, Jacks T. The retinoblastoma gene family in differentiation and development. Oncogene. 1999;18:7873-7882[CrossRef][Medline] [Order article via Infotrieve]. 28. Grana X, Garriga J, Mayol X. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene. 1998;17:3365-3383[CrossRef][Medline] [Order article via Infotrieve].
29.
Westin EH, Gallo RC, Arya SK, et al.
Differential expression of the amv gene in human hematopoietic cells.
Proc Natl Acad Sci U S A.
1982;79:2194-2198 30. Henriksson M, Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. Adv Cancer Res. 1996;68:109-182[Medline] [Order article via Infotrieve].
31.
Collins SJ.
The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression.
Blood.
1987;70:1233-1244 32. Brooks SC III, Sturgill R, Choi J, Yen A. An RXR-selective analog attenuates the RAR alpha-selective analog-induced differentiation and non-G1-restricted growth arrest of NB4 cells. Exp Cell Res. 1997;234:259-269[CrossRef][Medline] [Order article via Infotrieve]. 33. Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 1996;15:6595-6604[Medline] [Order article via Infotrieve]. 34. Perez-Roger I, Solomon DL, Sewing A, Land H. Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene. 1997;14:2373-2381[CrossRef][Medline] [Order article via Infotrieve].
35.
Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE.
Cyclin E-CDK2 is a regulator of p27Kip1.
Genes Dev.
1997;11:1464-1478 36. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 1997;16:5334-5344[CrossRef][Medline] [Order article via Infotrieve].
37.
Oberg F, Larsson LG, Anton R, Nilsson K.
Interferon gamma abrogates the differentiation block in v-myc-expressing U-937 monoblasts.
Proc Natl Acad Sci U S A.
1991;88:5567-5571
38.
Steinman RA, Huang J, Yaroslavskiy B, Goff JP, Ball ED, Nguyen A.
Regulation of p21(WAF1) expression during normal myeloid differentiation.
Blood.
1998;91:4531-4542 39. Casini T, Pelicci PG. A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. Oncogene. 1999;18:3235-3243[CrossRef][Medline] [Order article via Infotrieve].
40.
Taniguchi T, Endo H, Chikatsu N, et al.
Expression of p21(Cip1/Waf1/Sdi1) and p27(Kip1) cyclin-dependent kinase inhibitors during human hematopoiesis.
Blood.
1999;93:4167-4178
41.
Yaroslavskiy B, Watkins S, Donnenberg AD, Patton TJ, Steinman RA.
Subcellular and cell-cycle expression profiles of CDK-inhibitors in normal differentiating myeloid cells.
Blood.
1999;93:2907-2917 42. Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H. Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J. 1999;18:5310-5320[CrossRef][Medline] [Order article via Infotrieve]. 43. Bouchard C, Thieke K, Maier A, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999;18:5321-5333[CrossRef][Medline] [Order article via Infotrieve]. 44. Yang W, Shen J, Wu M, et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 2001;20:1688-1702[CrossRef][Medline] [Order article via Infotrieve]. 45. Furukawa Y, Kikuchi J, Nakamura M, Iwase S, Yamada H, Matsuda M. Lineage-specific regulation of cell cycle control gene expression during haematopoietic cell differentiation. Br J Haematol. 2000;110:663-673[CrossRef][Medline] [Order article via Infotrieve]. 46. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 1999;98:859-869[CrossRef][Medline] [Order article via Infotrieve].
47.
Lundberg AS, Weinberg RA.
Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.
Mol Cell Biol.
1998;18:753-761
48.
Bergh G, Ehinger M, Olofsson T, et al.
Altered expression of the retinoblastoma tumor-suppressor gene in leukemic cell lines inhibits induction of differentiation but not G1-accumulation.
Blood.
1997;89:2938-2950
49.
Rots NY, Iavarone A, Bromleigh V, Freedman LP.
Induced differentiation of U937 cells by 1,25-dihydroxyvitamin D3 involves cell cycle arrest in G1 that is preceded by a transient proliferative burst and an increase in cyclin expression.
Blood.
1999;93:2721-2729
50.
Liu Q, VanHoy RW, Zhou JH, Dantzer R, Freund GG, Kelley KW.
Elevated cyclin E levels, inactive retinoblastoma protein, and suppression of the p27(KIP1) inhibitor characterize early development of promyeloid cells into macrophages.
Mol Cell Biol.
1999;19:6229-6239 51. May JS, Prince AM, Lyle RE, McGehee RE Jr. Antisense suppression of p107 inhibits 3T3-L1 adipocyte differentiation. Biochem Biophys Res Commun. 2001;283:837-842[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  B. Trojanowicz, A. Winkler, K. Hammje, Z. Chen, C. Sekulla, D. Glanz, C. Schmutzler, B. Mentrup, S. Hombach-Klonisch, T. Klonisch, et al. Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines J. Mol. Endocrinol., March 1, 2009; 42(3): 249 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Acosta, N. Ferrandiz, G. Bretones, V. Torrano, R. Blanco, C. Richard, B. O'Connell, J. Sedivy, M. D. Delgado, and J. Leon Myc Inhibits p27-Induced Erythroid Differentiation of Leukemia Cells by Repressing Erythroid Master Genes without Reversing p27-Mediated Cell Cycle Arrest Mol. Cell. Biol., December 15, 2008; 28(24): 7286 - 7295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hattori, X. Zhang, Y. Jia, K. K. Subramanian, H. Jo, F. Loison, P. E. Newburger, and H. R. Luo RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells Blood, July 15, 2007; 110(2): 640 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, F. Li, X. Liu, L. Shen, J. Liu, J. Su, W. Zhang, Y. Deng, L. Wang, N. Liu, et al. The Repression of Human Differentiation-related Gene NDRG2 Expression by Myc via Miz-1-dependent Interaction with the NDRG2 Core Promoter J. Biol. Chem., December 22, 2006; 281(51): 39159 - 39168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C Dhulipala, W. V Welshons, and C. S Reddy Cell cycle proteins in normal and chemically induced abnormal secondary palate development: a review Human and Experimental Toxicology, November 1, 2006; 25(11): 675 - 682. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Ramljak, L. J. Romanczyk, L. J. Metheny-Barlow, N. Thompson, V. Knezevic, M. Galperin, A. Ramesh, and R. B. Dickson Pentameric procyanidin from Theobroma cacao selectively inhibits growth of human breast cancer cells Mol. Cancer Ther., April 1, 2005; 4(4): 537 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guidoboni, P. Zancai, R. Cariati, S. Rizzo, J. Dal Col, A. Pavan, A. Gloghini, M. Spina, A. Cuneo, F. Pomponi, et al. Retinoic Acid Inhibits the Proliferative Response Induced by CD40 Activation and Interleukin-4 in Mantle Cell Lymphoma Cancer Res., January 15, 2005; 65(2): 587 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Harris, B. Ozpolat, F. Abdi, S. Gu, A. Legler, K. G. Mawuenyega, M. Tirado-Gomez, G. Lopez-Berestein, and X. Chen Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia Blood, September 1, 2004; 104(5): 1314 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Walkley, L. E. Purton, H. J. Snelling, Y.-D. Yuan, H. Nakajima, P. Chambon, R. A. S. Chandraratna, and G. A. McArthur Identification of the molecular requirements for an RAR{alpha}-mediated cell cycle arrest during granulocytic differentiation Blood, February 15, 2004; 103(4): 1286 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Moqattash and J. D. Lutton Leukemia Cells and the Cytokine Network: Therapeutic Prospects Experimental Biology and Medicine, February 1, 2004; 229(2): 121 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gery, A. F. Gombart, Y. K. Fung, and H. P. Koeffler C/EBP{epsilon} interacts with retinoblastoma and E2F1 during granulopoiesis Blood, February 1, 2004; 103(3): 828 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Gadhoum, M.-P. Leibovitch, J. Qi, D. Dumenil, L. Durand, S. Leibovitch, and F. Smadja-Joffe CD44: a new means to inhibit acute myeloid leukemia cell proliferation via p27Kip1 Blood, February 1, 2004; 103(3): 1059 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lai, B. L. Bohnsack, K. Niederreither, and K. K. Hirschi Retinoic acid regulates endothelial cell proliferation during vasculogenesis Development, December 29, 2003; 130(26): 6465 - 6474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhang, N. Zheng, and P. Zhou Exploring the functional complexity of cellular proteins by protein knockout PNAS, November 25, 2003; 100(24): 14127 - 14132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Favot, S. Martin, T. Keravis, R. Andriantsitohaina, and C. Lugnier Involvement of cyclin-dependent pathway in the inhibitory effect of delphinidin on angiogenesis Cardiovasc Res, August 1, 2003; 59(2): 479 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dimberg, I. Karlberg, K. Nilsson, and F. Oberg Ser727/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0/G1 arrest of U-937 cells Blood, July 1, 2003; 102(1): 254 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sarkar, M. Leszczyniecka, D.-c. Kang, I. V. Lebedeva, K. Valerie, S. Dhar, T. K. Pandita, and P. B. Fisher Down-regulation of Myc as a Potential Target for Growth Arrest Induced by Human Polynucleotide Phosphorylase (hPNPaseold-35) in Human Melanoma Cells J. Biol. Chem., June 27, 2003; 278(27): 24542 - 24551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Despouy, J.-N. Bastie, S. Deshaies, N. Balitrand, A. Mazharian, C. Rochette-Egly, C. Chomienne, and L. Delva Cyclin D3 Is a Cofactor of Retinoic Acid Receptors, Modulating Their Activity in the Presence of Cellular Retinoic Acid-binding Protein II J. Biol. Chem., February 14, 2003; 278(8): 6355 - 6362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Niles Vitamin A (Retinoids) Regulation of Mouse Melanoma Growth and Differentiation J. Nutr., January 1, 2003; 133(1): 282S - 286. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
70°C. Inductions were done on exponentially growing
cells using 1 µM ATRA for the indicated time periods.
), cyclin B (
), cyclin E (
), p27
(*). (B) Kinetics of pRb dephosphorylation at specific sites based on
the quantification of Western blot data from Figure